DTx Pharma achieves proof of concept in primary human cells
DTx Pharma, a RNA-based therapeutics company, announced that they achieved their 2017 goal of demonstrating that that their technology enabled delivery of oligonucleotide therapeutics in vitro (cell lines) and ex vivo (cells isolated from human patients). In Q1, 2018, they will be evaluating delivery of their oligonucleotide therapeutics in animals.
DTx Pharma accepted into CONNECT Springboard Accelerator Program
DTx Pharma, a RNA-based therapeutics company, announced that it has been accepted into the prestigious CONNECT mentoring program. CONNECT is a program whose graduates have gone onto raise over $1.5 billion dollars in capital and whose companies have created over 4000 jobs. DTx entered expects to graduate in Q2, 2017. Further details on the CONNECT Springboard Accelerator Program are available at http://connect.catalyst-inc.org/springboard-accelerator.
DTx Pharma mentioned by JNJ executive as one of the world’s 20 hottest startups following JLABs portfolio showcase
DTx Pharma, a RNA-based therapeutics company, announced that it was one of 3 companies chosen from the JLABs San Diego site to present a 3-minute pitch to a global audience of investors, executives, physicians, strategic investors and government partners located in New York, San Francisco, Boston, Toronto, Houston and San Diego. Following the presentation, DTx was featured in a note and photograph by Arjun Desai, Vice President of Innovation at Johnson & Johnson, “as one of the 20 hottest startups in the world”.
DTx Pharma adds Jeff Friedman, MD, PhD, Neil Gibson, PhD, and Timothy Scott, JD to Scientific Advisory Board
DTx Pharma, a RNA-based therapeutics company, announced that Jeff Friedman, Neil Gibson and Timothy Scott joined the scientific advisory board in Q3, 2017 Dr. Friedmans the chair of the life sciences arm of the Tech Coast Angels, the managing partner of Friedman Bioventures and serves as Director and Chair of the research committee of CurePSP. Dr. Gibson is currently the chief scientific officer, biologics at COI pharmaceuticals. Previously, he served as the chief scientific officer for Regulus Therapeutics, chief scientific officer and oncology therapeutic area head at Pfizer as well as senior Vice President at BioAtla. Mr. Scott is currently the chief executive officer of TEGA therapeutics and serves on the board of Avelas and Orphan Pharmaceuticals. Last year, he sold a company he founded, Pharmatek, to Catalent Therapeutics.